These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 38251484

  • 1. Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study.
    Cho J, Shen L, Huq M, Kandane-Rathnayake R, Golder V, Louthrenoo W, Chen YH, Hamijoyo L, Luo SF, Wu YJ, Zamora L, Li Z, Sockalingam S, Katsumata Y, Harigai M, Hao Y, Zhang Z, Basnayake D, Chan M, Kikuchi J, Takeuchi T, Bae SC, Oon S, O'Neill S, Goldblatt F, Ng KPL, Law A, Tugnet N, Kumar S, Tee C, Tee M, Ohkubo N, Tanaka Y, Navarra SV, Lau CS, Hoi A, Morand EF, Nikpour M, Lateef A, Asia-Pacific Lupus Collaboration.
    Lancet Rheumatol; 2023 Oct; 5(10):e584-e593. PubMed ID: 38251484
    [Abstract] [Full Text] [Related]

  • 2. Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study.
    Golder V, Kandane-Rathnayake R, Li N, Louthrenoo W, Chen YH, Cho J, Lateef A, Hamijoyo L, Luo SF, Wu YJ, Navarra SV, Zamora L, Li Z, Sockalingam S, Katsumata Y, Harigai M, Hao Y, Zhang Z, Basnayake D, Chan M, Kikuchi J, Takeuchi T, Bae SC, Goldblatt F, Oon S, O'Neill S, Ng K, Law A, Tugnet N, Kumar S, Tee C, Tee M, Ohkubo N, Tanaka Y, Lau CS, Hoi A, Nikpour M, Morand EF, Asia Pacific Lupus Collaboration.
    Lancet Rheumatol; 2024 Aug; 6(8):e528-e536. PubMed ID: 38876129
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study.
    Golder V, Kandane-Rathnayake R, Huq M, Louthrenoo W, Luo SF, Wu YJ, Lateef A, Sockalingam S, Navarra SV, Zamora L, Hamijoyo L, Katsumata Y, Harigai M, Chan M, O'Neill S, Goldblatt F, Lau CS, Li ZG, Hoi A, Nikpour M, Morand EF, Asia Pacific Lupus Collaboration.
    Lancet Rheumatol; 2019 Oct; 1(2):e103-e110. PubMed ID: 38229337
    [Abstract] [Full Text] [Related]

  • 4. Predictors of flare in SLE patients fulfilling lupus low disease activity state: a cohort study of 292 patients with 36-month follow-up.
    Cunha RN, Saraiva L, Jesus D, Doria A, da Silva JP, Inês LS.
    Rheumatology (Oxford); 2023 Nov 02; 62(11):3627-3635. PubMed ID: 36847423
    [Abstract] [Full Text] [Related]

  • 5. Association of systemic lupus erythematosus standard of care immunosuppressants with glucocorticoid use and disease outcomes: a multicentre cohort study.
    de Luca Montes RA, Huq M, Godfrey T, Oon S, Calderone A, Kandane-Rathnayake R, Louthrenoo W, Luo SF, Jan Wu YJ, Golder V, Lateef A, Navarra SV, Zamora L, Hamijoyo L, Sockalingam S, An Y, Li Z, Katsumata Y, Harigai M, Chan M, Goldblatt F, O'Neill S, Lau CS, Cho J, Hoi A, Karyekar CS, Morand EF, Nikpour M.
    Adv Rheumatol; 2024 May 08; 64(1):38. PubMed ID: 38720354
    [Abstract] [Full Text] [Related]

  • 6. Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study.
    Hao Y, Ji L, Gao D, Fan Y, Geng Y, Zhang X, Li G, Zhang Z.
    Lupus Sci Med; 2022 Mar 08; 9(1):. PubMed ID: 35241499
    [Abstract] [Full Text] [Related]

  • 7. Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study.
    Kandane-Rathnayake R, Golder V, Louthrenoo W, Chen YH, Cho J, Lateef A, Hamijoyo L, Luo SF, Wu YJ, Navarra SV, Zamora L, Li Z, Sockalingam S, Katsumata Y, Harigai M, Hao Y, Zhang Z, Basnayake BMDB, Chan M, Kikuchi J, Takeuchi T, Bae SC, Oon S, O'Neill S, Goldblatt F, Ng KPL, Law A, Tugnet N, Kumar S, Tee C, Tee M, Ohkubo N, Tanaka Y, Yu D, Karyekar CS, Sing Lau C, Monk JA, Nikpour M, Hoi A, Morand EF, Asia-Pacific Lupus Collaboration.
    Lancet Rheumatol; 2022 Dec 08; 4(12):e822-e830. PubMed ID: 38261390
    [Abstract] [Full Text] [Related]

  • 8. Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study.
    Nikoloudaki M, Nikolopoulos D, Koutsoviti S, Flouri I, Kapsala N, Repa A, Katsimbri P, Theotikos E, Pitsigavdaki S, Pateromichelaki K, Bertsias A, Elezoglou A, Sidiropoulos P, Fanouriakis A, Boumpas D, Bertsias G.
    Front Immunol; 2022 Dec 08; 13():1074044. PubMed ID: 36685524
    [Abstract] [Full Text] [Related]

  • 9. Predicting flares in patients with stable systemic lupus erythematosus.
    Cho J, Lahiri M, Teoh LK, Dhanasekaran P, Cheung PP, Lateef A.
    Semin Arthritis Rheum; 2019 Aug 08; 49(1):91-97. PubMed ID: 30660381
    [Abstract] [Full Text] [Related]

  • 10. Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study.
    Connelly K, Kandane-Rathnayake R, Hoi A, Louthrenoo W, Hamijoyo L, Cho J, Lateef A, Fen Luo S, Wu YJ, Li Z, Navarra S, Zamora L, Sockalingam S, Hao Y, Zhang Z, Katsumata Y, Harigai M, Oon S, Chan M, Chen YH, Bae SC, O'Neill S, Goldblatt F, Kikuchi J, Takeuchi T, Ling Ng KP, Tugnet N, Basnayake BMDB, Ohkubo N, Tanaka Y, Sing Lau C, Nikpour M, Golder V, Morand EF, Asia-Pacific Lupus Collaboration.
    Lancet Rheumatol; 2022 Dec 08; 4(12):e831-e841. PubMed ID: 38261391
    [Abstract] [Full Text] [Related]

  • 11. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission.
    Zen M, Iaccarino L, Gatto M, Saccon F, Larosa M, Ghirardello A, Punzi L, Doria A.
    Ann Rheum Dis; 2018 Jan 08; 77(1):104-110. PubMed ID: 28970217
    [Abstract] [Full Text] [Related]

  • 12. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
    Fanouriakis A, Adamichou C, Koutsoviti S, Panopoulos S, Staveri C, Klagou A, Tsalapaki C, Pantazi L, Konsta S, Mavragani CP, Dimopoulou D, Ntali S, Katsikas G, Boki KA, Vassilopoulos D, Konstantopoulou P, Liossis SN, Elezoglou A, Tektonidou M, Sidiropoulos P, Erden A, Sfikakis PP, Bertsias G, Boumpas DT.
    Semin Arthritis Rheum; 2018 Dec 08; 48(3):467-474. PubMed ID: 29555348
    [Abstract] [Full Text] [Related]

  • 13. Lupus low disease activity state within 12 months is associated with favourable outcomes in severely active systemic lupus erythematosus.
    Kikuchi J, Hanaoka H, Saito S, Oshige T, Hiramoto K, Kaneko Y, Takeuchi T.
    Rheumatology (Oxford); 2022 Aug 30; 61(9):3777-3791. PubMed ID: 35015824
    [Abstract] [Full Text] [Related]

  • 14. Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study.
    Golder V, Kandane-Rathnayake R, Huq M, Nim HT, Louthrenoo W, Luo SF, Wu YJ, Lateef A, Sockalingam S, Navarra SV, Zamora L, Hamijoyo L, Katsumata Y, Harigai M, Chan M, O'Neill S, Goldblatt F, Lau CS, Li ZG, Hoi A, Nikpour M, Morand EF, Asia-Pacific Lupus Collaboration.
    Lancet Rheumatol; 2019 Oct 30; 1(2):e95-e102. PubMed ID: 38229349
    [Abstract] [Full Text] [Related]

  • 15. Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression.
    Pitsigavdaki S, Nikoloudaki M, Garantziotis P, Silvagni E, Repa A, Marangoni A, Flouri I, Avgoustidis N, Parperis K, Fanouriakis A, Govoni M, Sidiropoulos P, Boumpas DT, Bortoluzzi A, Bertsias G.
    Ann Rheum Dis; 2024 Mar 12; 83(4):464-474. PubMed ID: 38233103
    [Abstract] [Full Text] [Related]

  • 16. Characterisation and outcomes of different subsets of low disease activity states in patients with systemic lupus erythematosus.
    Hao Y, Hansen D, Louthrenoo W, Chen YH, Cho J, Lateef A, Hamijoyo L, Luo SF, Wu YJ, Navarra S, Zamora L, Li Z, Sockalingam S, Katsumata Y, Harigai M, Zhang Z, Chan M, Kikuchi J, Takeuchi T, Bae SC, Goldblatt F, O'Neill S, Ng K, Basnayake BMDB, Tugnet N, Tanaka Y, Lau CS, Li N, Golder V, Hoi A, Kandane-Rathnayake R, Morand E, Oon S, Nikpour M.
    Lupus Sci Med; 2024 Sep 18; 11(2):. PubMed ID: 39299757
    [Abstract] [Full Text] [Related]

  • 17. Risk factors of disease flares in a Chinese lupus cohort with low-grade disease activity.
    Sun F, Zhao L, Wang H, Zhang D, Chen J, Wang X, Li T, Ye S.
    Lupus Sci Med; 2022 May 18; 9(1):. PubMed ID: 35606018
    [Abstract] [Full Text] [Related]

  • 18. Impact of teleconsultation on subsequent disease activity and flares in patients with systemic lupus erythematosus.
    Au Eong JTW, Lateef A, Liang S, Lim SHH, Tay SH, Mak A, Cho J.
    Rheumatology (Oxford); 2022 May 05; 61(5):1911-1918. PubMed ID: 34554232
    [Abstract] [Full Text] [Related]

  • 19. Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study.
    Apostolopoulos D, Kandane-Rathnayake R, Louthrenoo W, Luo SF, Wu YJ, Lateef A, Golder V, Sockalingam S, Navarra S, Zamora L, Hamijoyo L, Katsumata Y, Harigai M, Chan M, O'Neill S, Goldblatt F, Lau CS, Li ZG, Hoi A, Nikpour M, Morand E, Asia-Pacific Lupus Collaboration.
    Lancet Rheumatol; 2020 Jan 05; 2(1):e24-e30. PubMed ID: 38258272
    [Abstract] [Full Text] [Related]

  • 20. Remission and low disease activity in Polish patients with systemic lupus erythematosus - real-life, five-year follow-up outcomes.
    Pawlak-Buś K, Schmidt W, Leszczyński P.
    Eur Rev Med Pharmacol Sci; 2023 Feb 05; 27(3):949-959. PubMed ID: 36808341
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.